• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunomodulators Targeting MARCO Expression Improve Resistance to Post-influenza Bacterial Pneumonia

tetano

Editor, Senior Moderator
Am J Physiol Lung Cell Mol Physiol. 2017 Apr 13:ajplung.00075.2017. doi: 10.1152/ajplung.00075.2017. [Epub ahead of print]
[h=1]Immunomodulators Targeting MARCO Expression Improve Resistance to Post-influenza Bacterial Pneumonia.[/h] Wu M, Gibbons JG, Deloid GM[SUP]1[/SUP], Bedugnis AS, Thimmulappa RK[SUP]2[/SUP], Biswal S[SUP]3[/SUP], Kobzik L[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Down-regulation of the alveolar macrophage (AM) macrophage receptor with collagenous structure (MARCO) leads to susceptibility to post-influenza bacterial pneumonia, a major cause of morbidity and mortality. We sought to determine whether immunomodulation of MARCO could improve host defense and resistance to secondary bacterial pneumonia. RNAseq analysis identified a striking increase of MARCO expression between days 9 and 11 after influenza infection and indicated important roles for Akt and Nrf2 in MARCO recovery. In vitro, primary human AM-like monocyte-derived macrophages (AM-MDMs) and THP-1 macrophages were treated with IFNγ to model influenza effects. Activators of Nrf2 (sulforaphane) or Akt (SC79) caused increased MARCO expression and a MARCO-dependent improvement in phagocytosis in IFNγ-treated cells, and improved survival in mice with post-influenza pneumococcal pneumonia. Transcription factor analysis also indicated a role for transcription factor E-box (TFEB) in MARCO recovery. Overexpression of TFEB in THP-1 cells led to marked increases in MARCO. The ability of Akt activation to increase MARCO expression in IFNγ-treated AM-MDMs was abrogated in TFEB-knockdown cells, indicating Akt increases MARCO expression through TFEB. Increasing MARCO expression by targeting Nrf2 signaling or Akt-TFEB-MARCO pathway are promising strategies to improve bacterial clearance and survival in post-influenza bacterial pneumonia.
Copyright ? 2017, American Journal of Physiology-Lung Cellular and Molecular Physiology.


[h=4]KEYWORDS:[/h] MARCO; immunomodulators; influenza; scavenger receptors; secondary pneumonia

PMID: 28408365 DOI: 10.1152/ajplung.00075.2017
 
Back
Top Bottom